Scroll to walk the pathway — from β-catenin behaving normally at the membrane to the proposed biological consequence of lesion regression. The cell membrane stays structurally intact throughout.
In healthy behaviour, β-catenin contributes to cell–cell adhesion through cadherin-associated complexes. This is a legitimate, essential structural role — and NBetaX is designed to leave it untouched.
Disease-associated signalling increases the availability or activity of β-catenin. It escapes normal regulation and accumulates in the cytoplasm, becoming available for nuclear transport.
β-catenin travels toward the nuclear pores and enters the nucleus, where it can participate in transcriptional complexes.
Inside the nucleus, genes associated with persistence, invasion, inflammatory signalling, tissue remodelling and fibrosis may become activated — the biology that lets a lesion survive, invade and return.
N-BX01 is being engineered to interfere selectively with a molecular step required for pathological nuclear β-catenin activity — synthesized by Bogdan Dicoias on the SYNTHESERACT™ CF-SPPS machine. Useful β-catenin biology is preserved; pathological nuclear activity is excluded.
With the pathological nuclear route intercepted, disease-associated transcription fades. The lesion begins to lose the molecular advantage that sustains it.
Reduced lesion fitness could diminish invasive behaviour and permit regression, while immune-clearance cells enter the resolving tissue.
Proposed biological consequence — not a guaranteed resultEach step above rests on published Wnt/β-catenin science. The therapeutic hypothesis for endometriosis was stated in 2014 and reviewed in 2026; the closest preclinical precedent is an animal study, and the peptide modality is published in chemical-biology and oncology contexts. Animal and in vitro results are not evidence of effect in humans.